Jpmorgan Chase & CO Annexon, Inc. Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Annexon, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 46,886 shares of ANNX stock, worth $134,093. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,886
Previous 46,886
-0.0%
Holding current value
$134,093
Previous $139,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ANNX
# of Institutions
152Shares Held
101MCall Options Held
88.6KPut Options Held
32.5K-
Satter Management Co., L.P.7.41MShares$21.2 Million71.99% of portfolio
-
Bvf Inc San Francisco, CA7MShares$20 Million1.13% of portfolio
-
Black Rock Inc. New York, NY6.59MShares$18.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA6.3MShares$18 Million2.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.84MShares$16.7 Million0.0% of portfolio
About Annexon, Inc.
- Ticker ANNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,617,700
- Market Cap $136M
- Description
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...